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Abstract: BACKGROUND: Treatment of Crohn’s disease (CD) patients is complex as therapy choices
depend on a variety of factors, such as location and severity of inflammation, disease behavior (inflamma-
tory, stricturing or penetrating) but also comorbidities, extra-intestinal manifestations, the patient’s age,
and previous therapies. Subsequently, the choice of treatment should be tailored to the individual patient.
SUMMARY: This article gives the reader therapy algorithms as a guide through different CD scenarios
to support the physician’s decision making. New compounds introduced in CD therapy in recent years
justify such an update on standard approaches. Ustekinumab and vedolizumab and their positions within
the treatment options are discussed. Fistulizing perianal disease and postoperative medical prophylaxis
are depicted in separate chapters with own algorithms. Key Messages: In recent years, a variety of new
drugs became available to treat patients with CD - especially those who are antitumor necrosis factor
(TNF) experienced with ongoing inflammation. The definitive role of vedolizumab and ustekinumab is
not yet fully clarified. However, with the advantage of good safety profiles over TNF-inhibitors, these
drugs will be more frequently used in the near future, also as first-line biologicals, compared to TNF-
inhibitors. Concerning treatment of fistulizing disease, the knowledge of the exact anatomy of the fistula
is of major importance. An interdisciplinary discussion involving gastroenterologists, surgeons, and in
some cases gynecologists may help to optimize the treatment plan. Regarding the postsurgical setting
in CD patients, according to the very recent Cochrane Network meta-analysis, mesalazine should be at
least positioned equivalent to thiopurines and TNF-inhibitors, as shown in our algorithm.
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Abstract
Background: Treatment of Crohn’s disease (CD) patients is 
complex as therapy choices depend on a variety of factors, 
such as location and severity of inflammation, disease be-
havior (inflammatory, stricturing or penetrating) but also co-
morbidities, extra-intestinal manifestations, the patient’s 
age, and previous therapies. Subsequently, the choice of 
treatment should be tailored to the individual patient. Sum-
mary: This article gives the reader therapy algorithms as a 
guide through different CD scenarios to support the physi-
cian’s decision making. New compounds introduced in CD 
therapy in recent years justify such an update on standard 
approaches. Ustekinumab and vedolizumab and their posi-
tions within the treatment options are discussed. Fistulizing 
perianal disease and postoperative medical prophylaxis are 
depicted in separate chapters with own algorithms. Key 
Messages: In recent years, a variety of new drugs became 
available to treat patients with CD – especially those who are 
antitumor necrosis factor (TNF) experienced with ongoing 
inflammation. The definitive role of vedolizumab and 
ustekinumab is not yet fully clarified. However, with the ad-
vantage of good safety profiles over TNF-inhibitors, these 
drugs will be more frequently used in the near future, also as 
first-line biologicals, compared to TNF-inhibitors. Concern-
ing treatment of fistulizing disease, the knowledge of the 
exact anatomy of the fistula is of major importance. An inter-
disciplinary discussion involving gastroenterologists, sur-
geons, and in some cases gynecologists may help to opti-
mize the treatment plan. Regarding the postsurgical setting 
in CD patients, according to the very recent Cochrane Net-
work meta-analysis, mesalazine should be at least posi-
tioned equivalent to thiopurines and TNF-inhibitors, as 
shown in our algorithm. © 2020 S. Karger AG, Basel
Introduction
Crohn’s disease (CD) is a chronic inflammatory bowel 
disease (IBD) with relapsing and remitting symptoms that 
may lead to bowel damage and disability over time. There-
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fore, early diagnosis and adequate treatment should be 
achieved. Any part of the gastrointestinal tract can be af-
fected by CD, the most common being the terminal ileum 
and the colon. The disease phenotype is described by the 
Montreal classification (Table 1) that categorizes CD pa-
tients according to their age at diagnosis, location of the 
disease, and disease behavior [1]. The prospectively vali-
dated Lemann Damage Score might better represent accu-
mulating bowel damage over time [2, 3]. However, to date, 
there is no uniform reference standard to measure the inte-
gral disease burden in clinical practice. Indicators of severe 
disease course include smoking, sustained debilitating 
symptoms, repeated flare-ups, development of penetrating 
or stricturing lesions, need for repeated steroid treatment, 
and need for surgery [4]. Symptoms do not always correlate 
well with objective assessment such as endoscopy, cross-
sectional imaging, or noninvasive biomarkers. Addition-
ally, symptom scoring systems used in clinical trials (e.g., 
CD activity index) are not reliable measures of the underly-
ing inflammation and consequently have almost no role in 
clinical practice. Fecal calprotectin may act as surrogate 
marker of luminal intestinal inflammation as it correlates 
well with endoscopic disease activity [5, 6]. Endoscopy can 
reliably visualize mucosal inflammation and grade disease 
activity but may be difficult to achieve in case of small-bow-
el involvement. However, CD is a transmural disease that 
may be more reliably assessed with cross-sectional imaging 
(computed tomography, magnetic resonance imaging) or 
ultrasonography (US) [7, 8]. In clinical trials, patients are 
stratified into mild, moderate, or severe disease activity at a 
certain point in time with clinical scoring systems, for ex-
ample, CD activity index. However, these scores do not as-
sess overall disease burden and the patient’s risk profile. 
Clearly, there is a need for validated indices of severity [9].
Not only the abovementioned disease parameters but 
also the patient’s age, relevant comorbidities, possible ex-
tra-intestinal manifestations, previous therapies, and the 
presence of complicated disease risk factors [4, 10] (Table 
2) impact the individual therapeutic decision. Patient’s 
perception to treatment and also to the disease is one of 
the most important aspects to achieve good treatment ad-
herence [11]. Thus, the possibility to simplify CD treat-
ment is limited. Nevertheless, more general recommen-
dations certainly are possible and can be summarized in 
respective algorithms for CD treatment that support the 
physician’s decision to treat the patient as best as possible. 
The algorithms presented in this manuscript should point 
out the practicability of this review. They are based on the 
guidelines of the European Crohn’s and Colitis Organiza-
tion (ECCO) and include also their very recently pub-
lished updates (January 2020) [12–14] and are expert 
based opinions (without voting). A systematic review of 
the literature was not repeated (but done for the ECCO 
guidelines). Based on the current literature, we aimed to 
position recently approved drugs such as ustekinumab 
and vedolizumab within the therapy algorithm.
Table 1. Montreal classification [1]
Age at diagnosis
A1 below 16 years
A2 between 17 and 40 years










p perianal disease modifier†
The Montreal classification characterizes the phenotype of CD 
according to the patient’s age at diagnosis, the location of inflamma-
tion within the gastrointestinal tract, and also the disease behavior.
* L4 is a modifier that can be added to L1–L3 when upper gas-
trointestinal disease is coexistent.
† “p” is added to B1–B3 when concomitant perianal disease is 
present.
A, age at diagnosis; L, location of disease; B, behavior of disease; 
p, perianal disease; CD, Crohn’s disease.
Table 2. Indicators for severe disease/disease progression [4, 10]
Indicator
Young age at diagnosis
Corticoid steroids necessary at time of diagnosis
Early stricturing or penetrating disease (B2 and/or B3a)
Ileal or ileocolonic disease location (L1 or L3a)
Rectal disease





NOD2-mutation (risk for ileal disease/risk of surgery)
a According to the Montreal classification (Table 1).
This table shows a list of indicators that are associated with a 
severe disease course and disease progression in patients with CD.
CD, Crohn’s disease; NOD2, nucleotide-binding oligomeriza-
tion domain-containing protein 2.
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Medical Therapy for CD
Historically, treatment of CD has relied mainly on cor-
ticosteroids and immunosuppressive medication with 
thiopurines (azathioprine [AZA]/5-mercaptopurin [5-
MP]) or methotrexate (MTX; Table 3). Though the intro-
duction of corticosteroids achieved reduction of mortal-
ity in CD patients, this treatment is associated with many 
well-known undesired adverse effects and therefore not 
useful for long-term treatment. Two decades ago, the 
treatment armentarium was extended by infliximab, the 
first tumor necrosis factor (TNF)-inhibitor, especially for 
Table 3. List of medications for CD [15]
Agent Dosage
5-Aminosalicylic acid
Mesalazine Above 2.4 g/day
Corticosteroids
Budesonide 9 mg/day
Prednisone 0.75–1 mg/kg body weight/day
Immunosuppressive agents
AZA 2–2.5 (max. 3) mg/kg body weight/day
6-MP 1–1.5 mg/kg body weight/day





Adalimumab (Humira®/Hyrimoz®/Amgevita®) Subcutaneous injection
Week 0: 160 mg
Week 2: 80 mg
Week 4: 40 mg
Then, every other 2 weeks: 40 mg
Infliximab (Remicade®/Inflectra®/Remsima®) Infusion over 30–90 min
Week 0: 5 mg/kg
Week 2: 5 mg/kg
Week 6: 5 mg/kg
Then, every 8 weeks: 5 mg/kg
Certolizumab pegol* (Cimzia®) Subcutaneous injection
Week 0: 400 mg
Week 2: 400 mg
Week 4: 400 mg
Then, every 4 weeks: 400 mg
Vedolizumab (Entyvio®) Infusion over 30 min
Week 0: 300 mg
Week 2: 300 mg
Week 6: 300 mg
Then, every 8 weeks: 300 mg
Ustekinumab (Stelara®) Infusion week 0
≤55 kg 260 mg
55 to <85 kg 390 mg
>85 kg 520 mg
Then 90 mg subcutaneous injection 
after 8 weeks then every other 12 (or 8) weeks
* Certolizumab pegol is only approved in the United States and in Switzerland.
This table gives an overview of currently available drugs for the treatment of CD, grouped in mesalazine, cor-
ticosteroids, immunosuppressives, antibiotics (if indicated), and various biologicals. Common dosages are given. 
Biologicals which are not yet approved are not considered in this publication.
CD, Crohn’s disease; AZA, azathioprine; 6-MP, 6-mercaptopurine; MTX, methotrexate.
Sulz et al.Digestion4
DOI: 10.1159/000506364
patients with severe disease course and those who were 
refractory or intolerant to immunosuppressives [16]. 
However, therapy with TNF-inhibitors is still challenging 
as 20–40% of patients have primary nonresponse to the 
drug and 23–46% experience secondary loss of response 
over time [17]. In addition, approximately 5% of patients 
suffer from anti-TNF induced psoriasis [18] or lupus-like 
syndrome. Challenges also remain in treating elderlies 
who have significant comorbidities (e.g., heart failure) or 
patients with a history of malignancy.
Over the last couple of years, a number of new drugs 
have been developed and approved based either on inhi-
bition of immune cell trafficking or on inhibition of cyto-
kine signaling [19–22]. Vedolizumab, a monoclonal anti-
body directed against α4β7 integrin, has been approved 
for the treatment of patients with moderate-to-severe UC 
or CD who have inadequate response, loss of response or 
intolerance to conventional therapy with corticosteroids, 
immunosuppressives, or anti-TNF therapy. It is effective 
in the induction and maintenance of remission in refrac-
tory and luminal CD [23]. In real-world CD cohorts, clin-
ical remission and response rates after induction therapy 
(usually evaluated at week 14) ranged from 24–36% to 
49–64%, respectively, [24–27]. Vedolizumab prevents 
circulating immune cells from homing to the mucosa and 
is gut-selective through interactions with mucosal adhe-
sion molecules. This may be a specific advantage in long-
term safety [28] and may also explain the longer period of 
time to induce remission (12–16 weeks), compared to 
TNF-inhibitors. Therefore, vedolizumab is not the ideal 
choice in patients with severe CD who are acutely ill 
where fast response to treatment is needed. In the latest 
ECCO guideline [13], the position of vedolizumab is 
adapted as it is now also clearly recommended to be used 
for induction and remission in patients with moderate to 
severe CD with inadequate response to conventional 
therapy with immunosuppressives. In other words, it is 
recommended as a first-line biological. However, the 
ECCO guideline does not discuss in detail which patients 
should be commenced on vedolizumab or anti-TNF in-
hibitors. In our opinion, vedolizumab is suitable as a first 
choice biological in elderlies with comorbidities and ele-
vated risk of infection and patients with history of malig-
nancy, where safety is of particular concern.
Ustekinumab is a monoclonal IgG1 antibody against 
the p40 subunit of interleukin-12 (IL-12) and IL-23 that 
targets T-helper cell pathways which promote the accu-
mulation of inflammatory cells within the intestine. It 
was approved for the treatment of patients with moder-
ate-to-severe CD who have failed or were intolerant to 
treatment with corticosteroids, immunosuppressives, or 
anti-TNF therapy. Ustekinumab has shown to be effec-
tive in inducing and maintaining remission [29, 30], with 
higher response rates in TNF-naïve than in TNF-experi-
enced patients (54–58% vs. 34%, respectively) [31]. In the 
updated ECCO guideline [13], ustekinumab has an ex-
panded position within the approved biologicals as it can 
also be used as a first-line biological – such as vedolizum-
ab. Again, the ECCO guideline does not give recommen-
dation where to prefer ustekinumab over TNF-inhibitors 
or over vedolizumab as first-line option. In our opinion, 
ustekinumab has its particular place as first-line biologi-
cal, especially in patients with psoriasis and CD. Further-
more, this drug is a suitable option in patients who have 
developed severe TNF-induced psoriasiform disease [18].
However, at least to date, TNF-inhibitors are less ex-
pensive (especially since biosimilars are available), and 
the clinical experience with TNF-inhibitors is much 
greater compared to the new biologicals. The safety pro-
file of both ustekinumab and vedolizumab seems favor-
able, but long-term safety still needs to be confirmed in 
postmarketing studies.
Therapy Algorithm for Endoluminal CD
The therapy algorithm for endoluminal CD (Fig.  1) 
guides the reader through different endoluminal CD sce-
narios. Ustekinumab and vedolizumab and their posi-
tions within the treatment options are discussed.
According to the ECCO guidelines [12, 13], budesonide 
(initially 9 mg) orally is the best treatment option for 
mildly active localized ileo-cecal disease to induce remis-
sion which can be achieved in up to 60% of patients after 
a therapy course over 8 weeks [37, 38]. For moderately 
active localized ileo-cecal disease, either budesonide or 
systemic oral corticosteroids are recommended. Usually, 
budesonide 9 mg daily is somewhat less effective than oral 
systemic steroids (relative risk [RR] 0.85, 95% CI 0.75–
0.97), especially in severe disease (RR 0.52, 95% CI 0.28–
0.95); however, oral budesonide is associated with less 
side effects (RR 0.64, 95% CI 0.54–0.76) [39, 40]. System-
ic corticosteroids are suitable in colonic and small bowel 
CD to induce remission [12].
For decades, mesalazine has been used to achieve re-
mission in CD. Still nowadays, mesalazine is often pre-
scribed; up to one-third of patients in the Epi-IBD cohort 
was treated with mesalazine [41]. However, the latest 
ECCO guidelines [13] suggest not to use mesalazine (or 
sulphasalazine) for CD treatment due to lack of support-
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1. Optimize by escalation (dose
 escalation or/and interval reduction)
2. Add AZA/6-MP, if possible
















Assessment of response after 2
weeks; tapering of corticosteroids
Response/remission
No response/no remission/recurrence
Fig. 1. Therapy algorithm for endoluminal CD [12, 13, 23, 29, 30, 
32–36]. To keep this algorithm as simple as possible and for rea-
sons of repetition and similarity, location and extent of inflamma-
tion (localized ileo-cecal, colonic, and extensive small bowel dis-
ease) are not specifically represented. Also, for reasons of simplic-
ity, the severity of inflammation (mild/moderately severe/severe) 
is not differentiated. However, high-risk situation for progressive 
disease and steroid-dependent/steroid-refractory inflammation 
are discussed as separate entities. Surgery as a therapeutic option 
in endoluminal CD treatment is integrated in the algorithm, where 
indicated. + For more details, see main text. % Budesonide: corti-
ment multi matrix is not approved for treatment of CD. # Table 1: 
indicators for severe disease/disease progression. & Anti-TNF: in-
fliximab and its biosimilars (Remicade®/Inflectra®/Remsima®); 
Adalimumab and its biosimilars (Humira®/Hyrimoz®/ 
Amgevita®); CertolizumabPegol (Cimzia®), only approved in 
Switzerland and USA. CD, Crohn’s disease; AZA, azathioprine; IL, 
interleukin; 6-MP, 6-mercaptopurine; MTX, methotrexate; TNF, 




ing data. The working group performed a meta-analysis 
of 7 randomised trials comparing mesalazine (5 studies) 
and sulphasalazine (2 studies), published in the supple-
ments [13]. The Cochrane Network meta-analyses are in-
consistent: A recent Cochrane Network meta-analysis by 
Coward et al. [42] demonstrated a significant benefit for 
high-dose mesalazine (above 2.4 g daily) over placebo 
(OR 2.29, 95% CI 1.58–3.33). However, another Network 
meta-analysis could not confirm such a dose effect [43]. 
Indeed, it has to be mentioned that the ECCO recommen-
dation is stated as “weak” and based only on moderate 
evidence. Furthermore, a risk-benefit analysis has not 
been performed. According to the meta-analysis, mesala-
zine is well tolerated [13]. In our opinion, mesalazine may 
still be a treatment option and may be offered to patients 
who refuse repetitive steroids or do not want to escalate 
therapy toward immunosuppressives or biologicals.
Local mesalazine (rectal foam/enema) in left-sided CD 
colitis is not recommended by the ECCO guidelines, due 
to lack of convincing data [12, 13]. This treatment has not 
been studied in randomized controlled studies. To date, 
budesonide multi matrix with a colonic delivery technol-
ogy is not (yet) approved for CD.
Generally, the response of induction therapy should be 
clinically assessed after 2 weeks. Usually, tapering of cor-
ticosteroids starts after 2 weeks. In selected cases (first 
flare and mild localized disease), no further therapy may 
be considered (ECCO statement 5 C; [12]). A population-
based study investigated the outcome of first steroid 
treatment in CD patients and revealed that 80% of the 
patients had a primary response within 30 days of therapy 
(48% with complete remission; 32% with partial re-
sponse). Of those, 55% had prolonged response within 
1 year. However, 45% had either a course of relapses or 
stayed steroid dependent [44]. Therefore, in around half 
of the patients, a concomitant therapy with either immu-
nosuppressive agents (AZA/6-MP or MTX) or biological 
treatment must be considered as a steroid-sparing con-
cept. Patients with several indicators predictive for a se-
vere disease course (Table 2) should be early commenced 
on a biological treatment. When TNF-inhibitors have be-
come available, early start of anti-TNF therapy in these 
patients increasingly became common practice, given the 
fact that continued treatment with either infliximab or 
adalimumab has been associated with a substantial reduc-
tion in hospitalisation (with adalimumab every other 
week: 52 and 48% relative reductions in 12-month risk of 
all-cause and CD-related hospitalisation, respectively) 
and surgery for CD (major surgery rate in the adalim-
umab every other week arm almost 7 times lower than 
that in the placebo arm [p < 0.05]) [45, 46]. The literature 
shows that combined treatment with infliximab and 
AZA (at least 6 months) is more effective than infliximab 
alone to induce and maintain remission without steroids 
(SONIC trial) [46, 47]. Of course, the treating physician 
has to bear in mind the patient’s individual situation 
 including safety profile. However, it must be stated that a 
significant reduction of surgery rates up to 40% has also 
been shown for thiopurines [48].
Generally, treatment in patients with extensive small 
bowel disease (defined as involvement of > 100 cm small 
bowel) should be more aggressive [49] and TNF-inhibi-
tors should be early started, also in combination with im-
munosuppressives, if possible [50]. Early start of anti-
TNF therapy is more effective in extensive disease than a 
late start [51, 52]. The CHARM trial with adalimumab 
could show that 60% of patients with CD < 2 years of du-
ration reached clinical remission, compared to 40% (p < 
0.05) of patients who had a longer duration of disease 
[51].
As mentioned, recently, new biologicals became avail-
able, such as the anti-α4β7-integrin monoclonal antibody 
vedolizumab, and the IL-12/23 p40 antibody ustekinu-
mab.  The updated ECCO guideline [13] recommends 
them to be used also as first-choice biologicals. Vedolizu-
mab (and also ustekinumab) may be preferred over TNF-
inhibitors in elderly patients or in patients with history of 
malignancy, as these drugs have a very good safety profile. 
However, one needs to bear in mind that vedolizumab is 
not effective against extraintestinal manifestations and is 
also not suitable when a fast response should be expected. 
Furthermore, ustekinumab is the preferred biological 
agent in  patients with coexistent psoriasis (see above).
Certainly, it is important to recognize patients who are 
steroid-dependent (defined as relapse within 12 weeks 
during tapering or tapering within 16 weeks impossible) 
or refractory to steroids (defined as nonresponse within 
4 weeks). In those patients, biological therapy should be 
initiated [53].
Patients with early relapses and frequent flares during 
immunosuppressive therapy should be commenced on 
biological treatment (see below). Alternatively, surgical 
resection can be discussed or evaluated, especially in lo-
calized disease and in those patients who still have active 
inflammation despite experience with all TNF-inhibitors 
and other biologicals.
Monitoring of patients with CD is important and is 
recommended by the ECCO guidelines [8]. In patients 
who reached clinical and biochemical remission, moni-
toring aims at early flare recognition [8]. According to 
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the ECCO guidelines fecal calprotectin can be used to 
detect relapse before clinical symptoms occur. The mon-
itoring time interval should be between 3 and 6 months 
depending upon duration of remission and current 
therapy [8]. Other than in North America, in Europe, 
especially in Germany and Switzerland, monitoring of 
IBD patients with US is much more common and fre-
quently performed by many gastroenterologists in clin-
ical practice. A German prospective multicenter study 
found that bowel US can be used to monitor disease ac-
tivity in patients with active CD [54]. This method seems 
to be a useful follow-up method to evaluate early trans-
mural changes in disease activity, in response to medical 
therapy [54]. Hence, US is implemented as one of the 
monitoring instruments in our therapy algorithm 
(Fig. 1).
In case of inadequate response or loss of response, dif-
ferent options can be chosen to optimize the treatment: 
Serum trough levels of biologicals, especially of TNF-in-
hibitors, can be monitored and dosage adapted if re-
quired, also called therapeutic drug monitoring (TDM). 
It is also possible to optimize the TNF-inhibitor therapy 
based on clinical judgement only, without measuring 
drug trough levels or anti-TNF antibodies. The updated 
ECCO guideline commented on this aspect that there is 
currently no evidence to recommend for or against the 
use of TDM to improve the clinical outcome [13]. This 
statement is based on the only randomized controlled, 
multicenter study with 69 patients that showed no sig-
nificant difference in improving clinical response be-
tween the TDM-group and the symptom-based group 
(57.6 vs. 52.8%; RR 1.09, 95% CI 0.71–1.67; p = 0.81) [55]. 
Overall, despite the limited evidence, TDM might bring a 
cost-saving benefit [56]. Adding AZA/5-MP or MTX 
could be another step to increase efficacy of TNF-inhibi-
tors, especially in patients treated with infliximab. In case 
of antibody formation against the TNF-inhibitor which 
was used (e.g., infliximab), a switch to another one (e.g., 
adalimumab or certolizumab pegol; certolizumab pegol 
approved for CD in Switzerland and United States) would 
be recommended (switch within class).
In patients with primary nonresponse despite ade-
quate dosage or intolerance to the drug, an alternative 
TNF-inhibitor or another class of biologicals (vedolizu-
mab or ustekinumab) must be selected. The preference 
should be given to change the mechanism of action.
Especially in localized ileo-cecal disease, surgery is also 
a reasonable option in patients who deny medical treat-
ment options (due to any reason) or in those who are not 
compliant toward medical therapy.
Esophageal and gastroduodenal disease: According to 
the ECCO statement 5 H, mild esophageal or gastroduo-
denal disease may be treated with proton pump inhibitors 
only [12]. However, it needs to be mentioned that CD in 
the proximal gut is associated with a worse prognosis 
[57]. Therefore, in general, more aggressive treatment 
should be recommended. Evidence-based therapy is 
mainly based on case series [58, 59]. Many clinicians add 
a proton pump inhibitor to conventional induction ther-
apy and have a low threshold for starting anti-TNF ther-
apy than for disease elsewhere. 
Therapy Algorithm for Fistulizing Disease
The knowledge of the exact anatomy of the fistula is of 
major importance in order to plan the treatment. An in-
terdisciplinary discussion involving gastroenterologists, 
surgeons, and in some cases gynecologists may help to 
optimize the treatment plan.
The proper assessment of fistulae by magnetic reso-
nance imaging, endosonography, and exploration under 
anesthesia allows to differentiate between simple perianal 
fistulae and complex fistulae according to Sandborn et al. 
[60] (Fig. 2). Complicated fistulae can be considered as a 
risk factor for poor prognosis and should therefore be ag-
gressively treated. These complex fistulae are: high (high 
means involving > 2/3 of the external sphincter) inter-
sphincteric, high transsphincteric, suprasphincteric, and 
extrasphincteric, may have multiple openings and may be 
associated with an abscess, proctitis, rectal stricture, or 
may be connected with the bladder or vagina [60]. Any 
anterior fistula in women is generally considered com-
plex due to potential genital complications [61]. In con-
trast, simple fistulae are low fistulae that involve superfi-
cial tissue and include subcutaneous and intersphincteric 
and intrasphincteric fistulae that remain below the den-
tate line, have a single opening, and are not associated 
with perianal complications [60, 61].
It is compulsory to rule out a perianal abscess first; 
perianal pain is almost always associated with an abscess. 
If suspected or already detected, urgent exploration un-
der anesthesia combined with drainage performed by a 
colorectal surgeon is the treatment of choice to prevent 
the destruction of undrained local sepsis. Furthermore, 
procto-sigmoidoscopy should be performed to search for 
active luminal disease. If detected, it must be treated 
achieving and maintaining remission [32].
An asymptomatic simple fistula does not need treat-
ment. When symptomatic, a simple fistula may be treated 
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conservatively (with antibiotics) and/or surgically by fis-
tulotomy (seton) after abscess formation has been ruled 
out. In case of nonresponse, anti-inflammatory therapy 
(either with immunosuppressives or with TNF-inhibi-
tors) should be added to gain healing [32].
Complex fistulae should be primarily treated with se-
tons and/or antibiotics and a biological treatment (usu-
ally a TNF-inhibitor) [14]. A systematic review of hetero-
geneous retrospective studies revealed that the combina-
tion of surgical and medical therapy may have a beneficial 
healing effect of perianal fistulae compared with surgery 
or medical therapy alone [59, 62]. To date, randomized 
controlled trials or prospective studies comparing anti-
TNF treatment alone versus anti-TNF and surgery com-
bined to treat complex perianal CD fistulae are not avail-
able [14]. If the treatment plan aims for fistula closure, the 
seton must be removed, often toward the end of the in-
duction phase of the TNF-inhibitor [63]. However, opti-
mal timing of removal is unknown. One option is to keep 
loose setons permanently in situ to control local sepsis 
and reduce symptoms, although they may need to be re-
placed at some time. Loose setons can also serve as a 
bridge between medical therapy and the definitive surgi-
cal treatment. Cutting setons are not recommended in the 
treatment of perianal CD as they are a method of fistu-
lotomy implicating a risk of sphincter injury [63].
Fistulectomy should only be used in selected cases due 
to the risk of fecal incontinence [32]. In severe therapy-
refractory fistulizing disease, fecal diversion with colos-
tomy or ileostomy may be evaluated. Often, this option is 
not easy to discuss with the individual patient. However, 
sometimes it is the only way to prevent further structural 
damage and to increase the healing of complex fistulae. It 
has to be stated that the fistula healing rate and stoma clo-
sure rate are limited [14]. For details concerning defini-
tive surgical treatments, it is referred to Gecse et al. [63], 
Adegbola et al. [64], and the updated ECCO guideline 
[14].
Several medications are used for the treatment of fistu-
lae. Antibiotics such as metronidazole and ciprofloxacin 
Recto-sigmoidoscopy
assess for proctitis
Perianal fistula Search/rule out local
sepsis rectal pain/
fever/induration
Classify type of fistula: simple or complex
assessment with MRI/EUS/EUA






Antibiotics (metronidazol or ciprofloxacin)
and/or seton◊ (or fistulotomy)

















Fig. 2. Management of fistulizing perianal 
disease [10, 12, 14, 32, 33, 36, 61]. Simple 
fistulae: Low fistulae that involve superfi-
cial tissue and include subcutaneous and 
intersphincteric and intrasphincteric fistu-
lae that remain below the dentate line, have 
a single opening and are not associated with 
perianal complications. Complex fistulae: 
are high (high means involving > 2/3 of the 
external sphincter) intersphincteric, high 
transsphincteric, suprasphincteric, and ex-
trasphincteric, may have multiple open-
ings, and may be associated with an abscess, 
proctitis, rectal stricture or may be connect-
ed with the bladder or vagina. ◊ Seton: Se-
ton, not cutting. AZA, azathioprine; EUA, 
examination under anesthesia; EUS, endo-
scopic ultrasonography; 6-MP, 6-mercap-
topurine; MRI, magnetic resonance imag-
ing; TNF, tumor necrosis factor.
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seem to be helpful and are frequently used to treat the infec-
tious complications of fistulizing disease. Only small stud-
ies are available, most of them showing that the therapeutic 
effect is limited to the time of antibiotic treatment. Antibi-
otics are useful to alleviate symptoms, but usually, they do 
not induce complete healing in complex fistulae [32]. Ac-
cording to the updated ECCO guideline, antibiotics have no 
role as monotherapy in closing fistulae [13]. Bacteria show 
increasing rates of resistance to ciprofloxacin; therefore this 
medication will have limited use in the future [65]. Steroids 
have not shown to play a role in the treatment of fistulae; 
they even may enhance septic complications. Thiopurines 
have been used in the treatment of fistula; however, there 
are limited data. A meta-analysis of 5 randomized, placebo-
controlled trials which assessed perianal fistula closure only 
as a secondary endpoint revealed that thiopurines were ef-
fective in inducing fistula closure (OR of response 4.44) 
[66]. However, a substantial number of patients needed to 
stop this treatment due to side effects [66]. Due to lack of 
data, the updated ECCO guideline suggested against using 
thiopurine monotherapy for fistula closure [13].
TNF-inhibitors are the medical mainstay in fistula 
treatment. The data from Present et al. [67] showed a sig-
nificant closure and response rate to infliximab. Howev-
er, it needs to be mentioned that the study endpoints were 
somewhat imprecise. The ECCO working groups per-
formed a meta-analysis of the existing data showing that 
infliximab was clearly effective in inducing (RR 3.57, 95% 
CI 1.38–9.25) and maintaining (RR 1.79, 95% CI 1.10–
2.92) clinical fistula healing [13]. The ECCO guideline 
clearly recommends infliximab as first-line biological for 
treating complex fistulizing CD [13]. Also adalimumab – 
although less strongly – is suggested to use for this indica-
tion by the ECCO guideline [13]. Adalimumab has shown 
to be effective in fistula closure in about 40% of cases [68]. 
In a small pediatric cohort, the fistula closure rate was 
44% [69]. The combined treatment with adalimumab and 
ciprofloxacin seems to be superior to an anti-TNF treat-
ment only; however, the positive effect is limited to the 
time the antibiotic is taken [70]. Adalimumab should be 
used in patients with previous infliximab failure as shown 
by the CHOICE trial [71]. Compared to the former ECCO 
guideline, the updated one does not support a decision for 
or against the use of thiopurines combined with TNF-
inhibitors to enhance the effect of anti-TNF in complex 
fistulizing disease [13]. A meta-analysis in 2015 based on 
11 randomized controlled trials revealed no apparent 
benefit from the above combined therapy as regards par-
tial (OR 1.25, 95% CI 0.84–1.88) or complete fistula clo-
sure (OR 1.1, 95% CI 0.68–1.78) [72].
To date, there are only few data available regarding the 
efficacy of ustekinumab in perianal CD. However, a 
French multi-center observational study (Bio-LAP) 
showed that ustekinumab appears as a fairly effective ther-
apeutic option in perianal refractory CD [70]. Among pa-
tients with setons at the time ustekinumab was started, 
successful seton ablation during follow-up was possible in 
29/88 (33%) [73]. In a recent systematic review and meta-
analysis of 27 controlled trials, a moderate-quality evi-
dence was found to support the efficacy of ustekinumab 
to induce fistula remission (RR 1.77, 95% CI 0.93–3.37) 
[74]. However, no difference was found for maintenance 
of remission, compared to placebo. Currently, the updat-
ed ECCO guideline stated that the evidence for ustekinum-
ab is insufficient for fistula healing [13]. For vedolizumab, 
only low-quality evidence was found in this meta-analysis 
[74]. Clearly, more studies are needed to define the role of 
ustekinumab and also vedolizumab related to other bio-
logical therapies for the management of refractory peri-
anal fistulizing CD. However, these biologicals may be 
used in TNF-refractory patients, or where TNF-inhibitors 
are contraindicated and luminal activity is also ongoing.
Recently, several studies about fistula curettage and 
mesenchymal stem cell therapy have been published and 
analyzed in a recent recent systematic review and meta-
analyis (23 studies with 696 patients) [75], showing sig-
nificant results concerning fistula closure (overall 80% 
success rate). However, the 4 randomized controlled tri-
als (483 patients) revealed a closure rate of 64% (vs. 37% 
in the control arm). The uncontrolled studies in this anal-
ysis most likely lead to overestimate the efficacy of this 
novel therapy. However, safety data are good and the re-
lapse rate is low. This costly treatment needs to be evalu-
ated in clinical practice and should be currently limited 
to refractory difficult to treat cases. Overall, complex peri-
anal fistulizing disease remains a challenging and limiting 
condition to treat. Further work is needed to optimize 
management in this special group of CD patients.
Algorithm for Postsurgical Prophylaxis
Unfortunately, for the majority of CD patients, surgery 
is not curative. The cumulative rate of symptomatic (clin-
ical) recurrence is high (at 3 years approximately 50%) 
[76]. Endoscopic assessment of the neoterminal ileum (il-
eocolonoscopy) is strongly recommended as gold stan-
dard for the diagnosis of postoperative endoscopic recur-
rence by the ECCO guidelines within the first year after 
surgery (EL2 [32]), based on the modified Rutgeert-Score 
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[76]. The endoscopic recurrence rate is even higher and 
predicts future clinical relapse. A meta-analysis showed an 
endoscopic recurrence rate of 58% (95% CI 51–65%) 1 
year (median) after surgery in the placebo groups of post-
operative maintenance trials [77]. Therefore, prevention 
of recurrence is an important part of the postsurgical 
management in CD patients. In this setting, a personal-
ized risk stratification with tailored therapy is eligible. 
However, despite a number of guidelines including the 
ECCO, the British Society of Gastroenterology, and 
 American College of Gastroenterology guidelines [32, 36, 
78], a robust algorithm for the prevention and treatment 
of postoperative recurrence is not yet established. The 
 algorithm presented in this publication is based on the 
available literature and our opinion and should help the 
reader as a recommendation in daily practice (Fig. 3).
A general prophylaxis with metronidazole (500 mg 
2–3 x/day; or ornidazole) limited to 3 months is easy to 
perform. Despite limited data and only moderate toler-
ance, this prophylaxis commenced directly after surgery 
is still recommended by the ECCO guidelines [32] and 
also by the recent consensus guidelines of the British So-
ciety of Gastroenterology [36]. Endoscopic recurrence at 
1 year was reduced by a 3-month metronidazole course, 
but not sustained beyond 12 months [80]. Decision mak-
ing in the postoperative setting is based on several factors, 
High risk
Previous resection(s) – perforating/penetrating
disease – smoker – extensive small bowel





















Metronidazole 500 mg 2–3×/day
for 3 months after surgery
(or ornidazole)
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smoking; refer to professional
cessation support
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Ileocolonoscopy 3–6 months after surgery
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Ileocolonoscopy 18 months after surgery
Fig. 3. Management of postoperative CD 
[12, 32, 33, 36, 79–81, 89]. Prevention of re-
currence is a relevant aspect of the postsur-
gical management in CD patients. A per-
sonalized risk stratification with tailored 
therapy is of relevance. Furthermore, the 
status of previous therapy and the patient’s 
attitude toward medical treatment should 
be considered. *  Prefer adalimuab [89]; 
+ for more details, see main text. AZA, aza-
thioprine; 6-MP, 6-mercaptopurine; TNF, 
tumor necrosis factor.
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mainly on the individual risk factors leading to the con-
stellation of either “low risk” or “high risk” (Fig. 3). Smok-
ing as the only modifiable risk factor is well replicated and 
associated with a 2-fold and a 2.5-fold increase in clinical 
and endoscopic recurrence, respectively, after surgery 
among smokers versus nonsmokers [82]. It has been 
shown that smoking cessation is correlated with a de-
creased risk of postoperative recurrence [83, 84]. It is of 
note that each smoking patient should be counseled about 
the importance to quit smoking. Professional cessation 
support (counseling, pharmacotherapy, or nicotine re-
placement therapy) should be offered with efforts (Fig. 3).
In patients with low risk (first resection, fibrostenotic 
disease, and nonsmoker), no further medical prophylaxis 
may be opted. In high-risk situations (≥1 previous resec-
tion, perforating disease, and smoker-status), prophylaxis 
with TNF-inhibitors and/or immunosuppressives (thio-
purines) are recommended as agents of choice by both, the 
ECCO and the American Gastroenterological Association 
guidelines [32, 85]. A more precise recommendation for 
the prevention of postoperative CD recurrence is missing 
in the guidelines. In 2014, a Cochrane review revealed that 
thiopurines had lower clinical relapse rates compared with 
placebo (RR 0.74, 95% CI 0.58–0.94), but with low-quality 
evidence [86]. However, a large placebo-controlled trial 
called TOPPIC (240 patients randomized to 6-MP at 1 mg/
kg/day versus placebo after surgery, follow-up for 3 years) 
showed a small but not significant effect of treatment (clin-
ical recurrence rate: 13% in the 6-MP group versus 23% in 
the placebo group, requiring medical or surgical interven-
tion [p = 0.07]) [87]. Interestingly, 60% of patients in the 
6-MP group had subtherapeutic levels at week 49. A sub-
group analysis revealed that 6-MP had a significant effect 
in reducing clinical recurrence in smokers compared with 
nonsmokers (p interaction = 0.018). Regarding TNF-in-
hibitors, the largest randomized placebo-controlled trial 
(called PREVENT; 297 patients with ileocolic resection 
and ileocolonic anastomosis and increased risk of recur-
rence, infliximab 8 weekly versus placebo) confirmed that 
TNF-inhibitors were effective to prevent postoperative re-
currence [88]. Although endoscopic recurrence was sig-
nificantly lower (22%) in the infliximab group than in the 
placebo group (51%; p < 0.001), the primary endpoint of 
this study, defined as clinical recurrence up to week 76, was 
not met (recurrence rates 13% for the infliximab group 
and 20% for the placebo group; p = 0.097).
Obviously, the newest Cochrane Network meta-analy-
sis published in September 2019 [89] puts current guide-
line recommendations on postoperative medical manage-
ment into a new perspective. These data reveal insufficient 
evidence to determine which treatment is safest or most 
effective in preventing clinical and endoscopic relapse be-
cause of very low certainty of evidence [89]. Partially, these 
new data conflict with recommendations of the current 
guidelines [32]. For example, the ECCO guidelines recom-
mend thiopurines or TNF-inhibitors as drug of choice to 
prevent postsurgical recurrence (EL2 [32]). High-dose me-
salazine is only declared as an option for patients with an 
isolated ileal resection (EL2 [32]). In contrast, according to 
the new network meta-analysis, there is only for mesala-
zine and adalimumab some evidence to prevent clinical 
relapse [89]. Based on these data, mesalazine should be at 
least positioned equivalent to thiopurines and TNF-inhib-
itors as shown in our algorithm (Fig. 3).
The choice of medical prophylaxis should also con-
sider the patient’s attitude toward medical treatment. 
Even in a high-risk situation, some patients prefer not to 
take medication after surgery, especially when they are 
feeling well or they fear possible side effects of medica-
tions. Compared to thiopurines and TNF-inhibitors, me-
salazine has a better overall safety profile which might be 
an argument to think of it. Alternatively, patients who are 
naïve to thiopurins can be commenced on AZA (or 
6-MP). In patients who had been preoperatively already 
on thiopurins, thiopurins are continued. In case of thio-
purine intolerance, anti-TNF therapy is commenced 
(Fig. 3). According to the new Cochrane Network meta-
analysis, adalimumab will probably have a stronger posi-
tion among the availale TNF-inhibitors [89].
In case the first postoperative endoscopic assessment 
shows no or mild inflammation (Rutgeert-Score < 2), pro-
phylaxis may be stopped. In cases of relevant mucosal in-
flammation (Rutgeerts 2 or above), escalation needs to be 
considered: Either starting medical treatment or switching 
from mesalazine to thiopurines or from thiopurines to TNF-
inhibitors or escalating the dosage of TNF-inhibitors. The 
strategy to use endoscopy in the decision making is mainly 
based on the data of the POCER trial, a large randomized 
clinical trial which provided evidence that endoscopy can 
guide postoperative CD management to lower the risk of 
recurrence [79]. The POCER trial compared an active care 
model using endoscopic assessment at 6 months postopera-
tively with standard care (no colonoscopy at 6 months). All 
patients received metronidazole for 3 months postopera-
tively; high-risk patients received thiopurines (or adalim-
umab in case of purine intolerance). In the case of 6-month 
endoscopic recurrence treatment step-up in the active care 
group was performed: to thiopurine, fortnightly adalimum-
ab with thiopurine, or weekly adalimumab, respectively. At 
18 months endoscopic recurrence was 49% in the active 
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clinical recurrence was 27 and 40%, respectively (p = 0.08) 
[79]. Thirty-nine percent of patients in the active care group 
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Closing Remarks and View on Emerging Therapies in 
CD
In recent years, a variety of new drugs became available 
to treat patients with CD – especially those who are anti-
TNF experienced with ongoing inflammation. Mean-
while, vedolizumab and ustekinumab are more clearly 
positioned not only as second-line but also as first-line 
biologicals besides TNF-inhibitors. With the advantage 
of good safety profiles (compared to TNF-inhibitors), 
these drugs will be more frequently used in the near fu-
ture. Certainly, it will be also a discussion whether vedol-
izumab will be a better option than AZA prior to anti-
TNF treatment, especially in elderly male patients with 
higher risk of lymphoma. However, this would negative-
ly impact the health costs in IBD-patients.
Certainly, the therapy algorithm of CD depicted in this 
article will be complemented by a variety of further 
emerging drugs which might be approved in the near fu-
ture, such as risankizumab and mirikizumab, anti-p19 
antibodies with selective activity against IL-23, and Janus 
kinase inhibitors, such filgotinib and upadacitinib as oral 
selective Janus kinase-1 inhibitors. Currently, large trials 
are ongoing.
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